Enixum, 4000 anti-ha me/0.4ml 0.4 ml 10 pcs

• Prevention of venous thrombosis and embolism in surgical interventions, especially in orthopedic and general surgical procedures;
• prevention of venous thrombosis and embolism in patients on bed rest due to acute therapeutic diseases, including acute heart failure and decompensation of chronic heart failure.Prevention of venous thrombosis and embolism in bedridden patients due to acute medical conditions, including acute heart failure and decompensation of chronic heart failure (NYHA class III or IV), acute respiratory failure; acute infectious diseases; acute stages of rheumatic diseases combined with a risk factor for venous thrombosis (see “Special Instructions. “
• treatment of deep vein thrombosis with or without pulmonary embolism;
• prevention of thrombosis in extracorporeal circulation during hemodialysis (usually with a session duration of 4 hours or less);
• treatment of unstable angina and myocardial infarction without Q-wave in combination with acetylsalicylic acid;
• treatment of acute ST-segment elevation myocardial infarction in patients undergoing drug treatment or subsequent percutaneous coronary intervention.

Active ingredient

Composition

How to take, the dosage

Interaction

Enixaparin sodium should not be alternated with other low molecular weight heparins, since they differ in manufacturing method, molecular weight, specific anti-Xa activity, units and dosage. As a consequence, preparations of low molecular weight heparins are characterized by different pharmacokinetics and biological activity (anti-IIa activity, interaction with platelets).

Enixum® is not recommended for use in combination with:

Hyperkalemia may occur with potassium salts, potassium-saving diuretics, angiotensin-converting enzyme inhibitors, angiotensin-II antagonists, cyclosporines, tacrolimus and trimethoprim.

The anticoagulant effect of enoxaparin sodium is enhanced with concomitant use with oral anticoagulants.

Concomitant use with platelet aggregation inhibitors (acetylsalicylic acid in antiplatelet doses in cardiac and neurological diseases, clopidogrel, abciximab, ticlopidine, eptifibatide, tirofiban, beraprost, iloprost) increases the risk of bleeding.

Special Instructions

Contraindications

Side effects

Overdose

Similarities